56.3 Chronic Electrolyte & Acid-Base Management in CKD

Chronic Metabolic Acidosis in CKD: Pathophysiology & Oral Alkali Therapy

Metabolic acidosis is an almost universal complication of progressive chronic kidney disease, typically emerging when the estimated GFR drops below 30 to 45 mL/min/1.73 m² (Stages G3b through G5).

Renal Acid-Base Physiology & Pathogenesis

Under normal physiological conditions, the human diet generates approximately 1 mEq/kg/day of non-volatile (fixed) acids (primarily sulfuric acid derived from the catabolism of sulfur-containing amino acids: methionine and cysteine). To maintain systemic acid-base equilibrium, the kidneys must perform two functions:

1. Reabsorb all filtered bicarbonate (~4,500 mEq/day), primarily in the proximal convoluted tubule.
2. Excrete the daily net fixed acid load through renal ammoniagenesis (proximal tubular conversion of glutamine into ammonium [$NH_4^+$] and alpha-ketoglutarate) and titratable acid excretion (primarily monobasic phosphate, $H_2PO_4^-$).

In chronic kidney disease, as functional nephron mass is destroyed:

• Early CKD (eGFR 30 to 60 mL/min): Total renal ammonium synthesis declines. The remaining intact nephrons maximally upregulate ammoniagenesis per nephron, but overall net acid excretion falls short. Retention of hydrogen ions with compensatory chloride retention produces a Normal Anion Gap (Hyperchloremic) Metabolic Acidosis.
• Advanced CKD (eGFR < 30 mL/min, Stages G4-G5): Renal excretion of unmeasured fixed organic and inorganic anions (sulfate, phosphate, urate, hippurate) fails. These retained anions accumulate in the circulation, converting the acid-base disorder into a High Anion Gap Metabolic Acidosis.

Adverse Systemic Sequelae of Chronic Acidosis

Chronic untreated metabolic acidosis is not merely a laboratory abnormality; it is an active driver of multi-organ decline:

• Accelerated Skeletal Muscle Proteolysis & Sarcopenia: Acidemia upregulates the ATP-dependent ubiquitin-proteasome proteolytic pathway and stimulates caspase-3 in skeletal myocytes. This drives rapid breakdown of myofibrillar proteins, inducing severe sarcopenia, frailty, and protein-energy wasting (PEW).
• Bone Demineralization & Osteopenia: Extracellular hydrogen ions are buffered directly by the skeleton. Protons stimulate osteoclasts and physicochemical dissolution of bone mineral (calcium hydroxyapatite, $Ca_{10}(PO_4)_6(OH)_2$), releasing carbonate, calcium, and phosphate into the circulation, worsening metabolic bone disease and arterial calcification.
• Accelerated CKD Progression: Intrarenal acidosis stimulates the local production of endothelin-1, angiotensin II, aldosterone, and the alternative complement pathway within renal tubules, generating chronic tubulointerstitial inflammation, capillary rarefaction, and progressive nephron fibrosis.
• Endocrine Dysregulation: Induces peripheral insulin resistance, impairs thyroid hormone metabolism, and suppresses growth hormone/IGF-1 signaling.

Treatment Targets & Oral Alkali Pharmacotherapy

                  KDIGO RECOMMENDATIONS FOR METABOLIC ACIDOSIS

   Parameter              Clinical Guideline Recommendation
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Serum Bicarbonate Goal Maintain serum bicarbonate >= 22 mEq/L (Target Range: 22 to 26 mEq/L)
                          Do NOT exceed 26 to 28 mEq/L (avoids metabolic alkalosis & calcification)

   First-Line Therapy     Oral Sodium Bicarbonate (NaHCO3) 650 mg tablets
                          • 1 tablet (650 mg) provides 7.7 mEq of bicarbonate and 7.7 mEq of sodium
                          • Starting Dose: 650 mg PO BID to TID (15 to 23 mEq/day)
                          • Titrate every 2-4 weeks until serum HCO3- is >= 22 mEq/L

   Alternative Therapy    Oral Sodium Citrate (Bicitra / Shohl solution)
                          • 1 mL provides 1 mEq sodium and 1 mEq bicarbonate equivalent
                          • Contraindication: NEVER co-administer with aluminum antacids!
                            (Citrate increases aluminum absorption tenfold, causing encephalopathy)

   Monitoring Priorities  Monitor office blood pressure, peripheral edema, and weight.
                          (Sodium bicarbonate causes significantly less volume expansion than NaCl)
   ═════════════════════════════════════════════════════════════════════════════════════════════

CKD-Mineral and Bone Disorder (CKD-MBD) & Secondary Hyperparathyroidism

CKD-Mineral and Bone Disorder (CKD-MBD) is a complex systemic syndrome that develops in virtually all patients with advanced CKD. It is defined clinically by a triad of interrelated pathology:

1. Biochemical abnormalities: Derangements in serum calcium, phosphorus, Parathyroid Hormone (PTH), Fibroblast Growth Factor 23 (FGF-23), and active vitamin D ($1,25(OH)_2D_3$).
2. Bone histomorphometry abnormalities (Renal Osteodystrophy): High-turnover bone disease (osteitis fibrosa cystica) vs. low-turnover bone disease (adynamic bone disease and osteomalacia).
3. Vascular and soft-tissue calcification: Medial arterial calcification (Mönckeberg sclerosis), coronary and peripheral artery calcification, cardiac valvular stenosis, and fatal calciphylaxis (calcific uremic arteriolopathy).

                THE PATHOPHYSIOLOGIC CASCADE OF CKD-MBD

   Progressive Loss of Nephron Mass (eGFR drops < 60 mL/min/1.73 m²)
                                    │
                                    ▼
   Impaired Renal Phosphate Filtration ──► Subtle Phosphate Retention
                                    │
                                    ▼
   Osteocytes Secrete Fibroblast Growth Factor 23 (FGF-23) [via Klotho co-receptor]
   (Compensatory phosphaturia keeps serum phosphorus normal early on)
                                    │
                                    ▼
   FGF-23 & Decreased Renal Mass Downregulate Renal 1-alpha-Hydroxylase (CYP27B1)
   (Inhibition of calcidiol conversion to active 1,25-dihydroxyvitamin D)
                                    │
                                    ▼
   Severe Deficiency of Active Calcitriol [1,25(OH)2D3]
                                    │
                                    ▼
   Impaired Intestinal Calcium Absorption ──► Hypocalcemia
                                    │
   ┌────────────────────────────────┴────────────────────────────────┐
   ▼                                                                 ▼
   Loss of Calcitriol-Mediated       Hypocalcemia (decreased CaSR)   Hyperphosphatemia
   Negative Feedback on Parathyroid  stimulates PTH transcription    stimulates PTH synthesis
   Gland pre-pro-PTH gene            and chief cell proliferation    directly
   └────────────────────────────────┬────────────────────────────────┘
                                    │
                                    ▼
                   SECONDARY HYPERPARATHYROIDISM (SHPT)
   (Massive parathyroid gland hyperplasia, osteoclast activation, renal osteodystrophy,
    subperiosteal bone resorption [rugger-jersey spine], vascular calcification)

Evidence-Based Treatment Strategies for CKD-MBD

                   PHARMACOTHERAPY SPECTRUM FOR CKD-MBD

   Drug Class & Agent          Mechanism of Action               Clinical Pearls & Safety Warnings
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Dietary Phosphate           Limits gastrointestinal           Daily target: 800 to 1,000 mg/day.
   Restriction                 phosphate load                    ELIMINATE processed food additives
                                                                 (fast foods, dark colas, processed meats;
                                                                 inorganic phosphate is 100% absorbed!)

   Calcium-Based Binders       Binds dietary phosphate in gut    First-line, inexpensive.
   • Calcium Acetate (PhosLo)  lumen to form insoluble           MANDATORY RULE: Limit total elemental
   • Calcium Carbonate (TUMS)  calcium phosphate, excreted       calcium from binders to < 1,500 mg/day
                               in feces. Must take WITH MEALS!   (total intake < 2,000 mg) to prevent
                                                                 severe arterial & valvular calcification!

   Non-Calcium Binders         Binds dietary phosphate in gut    PREFERRED when serum calcium is elevated
   • Sevelamer Carbonate       lumen WITHOUT absorbing calcium   (> 9.5-10.0 mg/dL), PTH is low, or severe
     (Renvela 800 mg TID)      or metals. Must take WITH MEALS!  vascular calcification is documented.
   • Lanthanum Carbonate                                         Sevelamer also binds bile acids, lowering
     (Fosrenol 500-1000 mg)                                      LDL-cholesterol by 15% to 30%.

   Active Vitamin D Sterols    Directly binds VDR in parathyroid Potently suppresses PTH transcription.
   • Calcitriol (oral/IV)      chief cells to downregulate       HIGH RISK of inducing hypercalcemia and
   • Paricalcitol (selective)  pre-pro-PTH gene transcription    hyperphosphatemia by stimulating GI absorption.
                                                                 Hold if Ca > 10.2 mg/dL or P > 5.5 mg/dL.

   Calcimimetics               Allosterically activates the      Suppresses PTH WITHOUT increasing calcium
   • Cinacalcet (Sensipar      Calcium-Sensing Receptor (CaSR)   or phosphorus (in fact, it LOWERS calcium!).
     30 to 90 mg daily)        on parathyroid chief cells,       Risk of symptomatic hypocalcemia;
   • Etelcalcetide (IV on HD)  increasing sensitivity to calcium monitor serum calcium within 1 week of start.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Chronic Hyperkalemia Management & Novel Intestinal Potassium Binders

Hyperkalemia is a life-threatening electrolyte derangement defined by a serum potassium > 5.0 mEq/L (severe if > 6.0 to 6.5 mEq/L), occurring with high frequency in patients with CKD Stages G3b through G5.

Pathophysiology of Hyperkalemia in CKD

Renal potassium elimination occurs almost exclusively in the cortical collecting duct (CCD) via principal cells:

1. Basolateral $Na^+/K^+$-ATPase pumps sodium out and potassium in.
2. Luminal epithelial sodium channels (ENaC) reabsorb sodium, creating a lumen-negative transepithelial potential difference.
3. This electrical gradient drives potassium secretion into the tubular lumen through ROMK (renal outer medullary potassium) channels and BK (big potassium / maxi-K) channels, stimulated by aldosterone and distal nephron sodium delivery.

In CKD, hyperkalemia develops from a confluence of factors: reduced total functioning nephron mass, impaired distal flow, tubular aldosterone unresponsiveness, metabolic acidosis (which shifts intracellular potassium into the extracellular compartment via $H^+/K^+$ exchange), and essential medications that block the renin-angiotensin-aldosterone axis (ACE inhibitors, ARBs, MRAs, beta-blockers, trimethoprim, NSAIDs).

The Modern Clinical Paradigm: Preserving Renoprotective Therapy

• The Historic Clinical Pitfall: Previously, when serum potassium reached 5.2 to 5.5 mEq/L, clinicians routinely discontinued ACE inhibitors, ARBs, and MRAs. Discontinuing these agents directly accelerates CKD progression and increases cardiovascular mortality.
• The Modern Guideline Approach: Current KDIGO 2024 guidelines strongly recommend maintaining and optimizing vital RAAS inhibitor therapy by utilizing dietary counseling and novel non-absorbed gastrointestinal potassium binders to manage serum potassium.

                NOVEL NON-ABSORBED POTASSIUM BINDERS

   Feature          Patiromer (Veltassa)                  Sodium Zirconium Cyclosilicate (SZC / Lokelma)
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════
   Chemical Nature  Non-absorbed cross-linked polymer bead Insoluble inorganic crystalline zirconium silicate

   Counter-Ion      Calcium-sorbitol complex              Sodium and hydrogen cations

   Primary Site     Distal colon                          Entire GI tract (stomach, small intestine, colon)
   of Action        (where luminal K+ concentration is highest) (Highly selective 3-Angstrom crystal micropores)

   Onset of Action  4 to 7 hours                          1 to 2 hours
                    (Slow onset; maintenance therapy)     (Rapid onset; useful for urgent correction)

   Dosing Regimen   8.4 g powder packet PO once daily     Correction: 10 g PO TID with water for up to 48 hours
                    with food; titrate up to 25.2 g daily Maintenance: 5 to 10 g PO once daily

   Critical Drug    SEPARATE BY AT LEAST 3 HOURS          SEPARATE BY AT LEAST 2 HOURS
   Interaction Rule from all other oral medications!      from drugs with pH-dependent gastric absorption
                    (Binds and reduces drug bioavailability) (e.g., azoles, protease inhibitors, levothyroxine)

   Adverse Effects  Constipation, diarrhea, flatulence;   Peripheral edema and sodium retention
                    Hypomagnesemia (binds Mg2+ in colon)  (Each 5 g dose contains ~400 mg elemental sodium)
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════

Anemia of Chronic Kidney Disease: Diagnostic Evaluation & ESA Protocol

Anemia is a characteristic complication of chronic kidney disease, typically manifesting when eGFR falls below 45 mL/min/1.73 m² and present in over 90% of patients with Stage G5 CKD. It contributes substantially to fatigue, cognitive impairment, left ventricular hypertrophy (LVH), heart failure decompensation, and cardiovascular mortality.

Multifactorial Pathophysiology of CKD Anemia

1. Primary Driver: Deficiency of Erythropoietin (EPO):
   • In healthy adults, >90% of erythropoietin is synthesized by specialized peritubular interstitial capillary fibroblasts in the renal cortex.
   • In CKD, progressive chronic tubulointerstitial inflammation, capillary rarefaction, and myofibroblast transdifferentiation lead to loss of functional EPO-producing cells, resulting in absolute erythropoietin deficiency.
2. Secondary Driver: Disordered Iron Homeostasis (Elevated Hepcidin):
   • Hepcidin is an acute-phase hepatic peptide that binds and degrades ferroportin, the sole cellular iron exporter on duodenal enterocytes and reticuloendothelial macrophages.
   • In CKD, reduced renal clearance of hepcidin combined with chronic low-grade systemic inflammation causes chronically elevated circulating hepcidin levels.
   • High hepcidin blocks intestinal iron absorption and traps iron inside macrophages (reticuloendothelial iron block), causing severe functional iron deficiency where bone marrow erythroid precursors are starved of iron despite normal or high total body iron stores.
3. Uremic Toxin-Mediated Erythrocyte Survival Shortening: Uremic milieu decreases red blood cell lifespan from the normal 120 days down to 60 to 90 days, compounded by microvascular blood loss from uremic platelet dysfunction.

Diagnostic Evaluation & Iron Repletion Targets

• Morphology: Classically normocytic, normochromic anemia with an inappropriately low reticulocyte count.
• Laboratory Workup: Complete blood count, absolute reticulocyte count, serum ferritin, and Transferrin Saturation (TSAT): $\text{TSAT (\%)} = \left( \frac{\text{Serum Iron}}{\text{Total Iron Binding Capacity [TIBC]}} \right) \times 100$
• MANDATORY CLINICAL RULE: Correct Iron Deficiency Prior to Initiating ESAs:
  • Erythropoiesis-Stimulating Agents (ESAs) drive rapid bone marrow erythropoiesis. If iron stores are insufficient, the patient will develop functional iron deficiency, rendering the ESA completely ineffective.
  • KDIGO Iron Targets Prior to & During ESA Therapy:
    • Transferrin Saturation (TSAT): Target > 20% (optimally 20% to 30%).
    • Serum Ferritin: Target > 100 ng/mL in non-dialysis CKD; Target > 200 ng/mL in maintenance hemodialysis CKD (optimally 200 to 500 ng/mL).
  • Route of Administration: In non-dialysis CKD, a 1- to 3-month trial of oral iron (ferrous sulfate 325 mg daily or ferric citrate) is reasonable; however, gastrointestinal intolerance and poor hepcidin-mediated absorption frequently necessitate Intravenous Iron (Iron Sucrose or Ferric Carboxymaltose), which is universally preferred in hemodialysis patients.

Erythropoiesis-Stimulating Agents (ESAs) & The FDA Black Box Warning

• Representative Agents:
  • Epoetin alfa (Epogen / Procrit): Recombinant human erythropoietin; administered SC or IV 1 to 3 times weekly (half-life ~8 hours IV, ~24 hours SC).
  • Darbepoetin alfa (Aranesp): Hyper-glycosylated erythropoietin analogue with 5 N-linked carbohydrate chains (compared to 3 in epoetin); extended terminal half-life (~25 hours IV, ~48 hours SC), allowing administration once weekly to once every 2 to 4 weeks.

                  ESA CLINICAL INITIATION & TARGETING PROTOCOL

   Clinical Decision Point    KDIGO & FDA Guideline Recommendation
   ═════════════════════════════════════════════════════════════════════════════════════════════
   When to INITIATE ESAs      Initiate ONLY when Hemoglobin is < 10.0 g/dL
                              (Ensure TSAT > 20% and Ferritin > 100 ng/mL first!)

   Target Hemoglobin Range    Target Hemoglobin: 10.0 to 11.5 g/dL (Maintenance target ~11.0 g/dL)

   FDA BLACK BOX WARNING:     TARGET HEMOGLOBIN MUST NEVER EXCEED 11.5 g/dL!
   Excess Cardiovascular Risk • Reduce dose by 25% if Hb increases > 1.0 g/dL in any 2-week period
                              • Hold dose if Hb approaches or exceeds 11.5 g/dL
                              • NEVER attempt to normalize hemoglobin (> 12.0 to 13.0 g/dL)!
   ═════════════════════════════════════════════════════════════════════════════════════════════

• The Evidence Behind the Black Box Warning: TREAT, CHOIR & CREATE Trials:
  • In the landmark TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy; 4,038 diabetic CKD patients) and CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) randomized controlled trials, targeting normal hemoglobin levels (Hb 13.0 to 14.0 g/dL) using high-dose ESAs resulted in:
    • A twofold increase in the risk of fatal and non-fatal ischemic stroke (HR 1.92).
    • Significant increases in venous thromboembolism (VTE), vascular access thrombosis (arteriovenous fistula clotting), and congestive heart failure hospitalizations.
    • Exacerbation of severe, uncontrolled hypertension.
    • Zero improvement in overall survival.
  • Consequently, ESAs are prescribed strictly to alleviate severe anemia symptoms and avoid allogeneic blood transfusions (which sensitize candidates to human leukocyte antigens [HLA], compromising future kidney transplant eligibility), maintaining hemoglobin strictly between 10.0 and 11.5 g/dL.